Suppr超能文献

视黄酸X受体结构动力学调节剂以揭示受体功能。

Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.

作者信息

Nahoum Virginie, Pérez Efrén, Germain Pierre, Rodríguez-Barrios Fátima, Manzo Fabio, Kammerer Sabrina, Lemaire Geraldine, Hirsch Oliver, Royer Catherine A, Gronemeyer Hinrich, de Lera Angel R, Bourguet William

机构信息

Institut National de la Santé et de la Recherche Médicale, U554, 34090 Montpellier, France.

出版信息

Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17323-8. doi: 10.1073/pnas.0705356104. Epub 2007 Oct 18.

Abstract

Retinoid X receptors (RXRalpha, -beta, and -gamma) occupy a central position in the nuclear receptor superfamily, because they form heterodimers with many other family members and hence are involved in the control of a variety of (patho)physiologic processes. Selective RXR ligands, referred to as rexinoids, are already used or are being developed for cancer therapy and have promise for the treatment of metabolic diseases. However, important side effects remain associated with existing rexinoids. Here we describe the rational design and functional characterization of a spectrum of RXR modulators ranging from partial to pure antagonists and demonstrate their utility as tools to probe the implication of RXRs in cell biological phenomena. One of these ligands renders RXR activity particularly sensitive to coactivator levels and has the potential to act as a cell-specific RXR modulator. A combination of crystallographic and fluorescence anisotropy studies reveals the molecular details accounting for the agonist-to-antagonist transition and provides direct experimental evidence for a correlation between the pharmacological activity of a ligand and its impact on the structural dynamics of the activation helix H12. Using RXR and its cognate ligands as a model system, our correlative analysis of 3D structures and dynamic data provides an original view on ligand actions and enables the establishment of mechanistic concepts, which will aid in the development of selective nuclear receptor modulators.

摘要

维甲酸X受体(RXRα、β和γ)在核受体超家族中占据核心地位,因为它们能与许多其他家族成员形成异源二聚体,从而参与多种(病理)生理过程的调控。选择性RXR配体,即所谓的类视黄醇X受体激动剂,已被用于或正在开发用于癌症治疗,并且有望用于治疗代谢性疾病。然而,现有类视黄醇X受体激动剂仍然存在重要的副作用。在此,我们描述了一系列从部分拮抗剂到纯拮抗剂的RXR调节剂的合理设计和功能特性,并证明了它们作为工具在探究RXR在细胞生物学现象中的作用的实用性。其中一种配体使RXR活性对共激活因子水平特别敏感,并且有潜力作为细胞特异性RXR调节剂发挥作用。晶体学和荧光各向异性研究相结合,揭示了激动剂到拮抗剂转变的分子细节,并为配体的药理活性与其对激活螺旋H12结构动力学的影响之间的相关性提供了直接实验证据。以RXR及其同源配体作为模型系统,我们对三维结构和动态数据的相关分析提供了关于配体作用的全新视角,并能够建立作用机制概念,这将有助于开发选择性核受体调节剂。

相似文献

1
Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17323-8. doi: 10.1073/pnas.0705356104. Epub 2007 Oct 18.
2
Modulation of RXR function through ligand design.
Biochim Biophys Acta. 2012 Jan;1821(1):57-69. doi: 10.1016/j.bbalip.2011.04.003. Epub 2011 Apr 16.
3
The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights.
PLoS One. 2010 Nov 30;5(11):e15119. doi: 10.1371/journal.pone.0015119.
5
Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
J Biol Chem. 2014 Jan 10;289(2):814-26. doi: 10.1074/jbc.M113.476861. Epub 2013 Nov 1.
6
Ligand Design for Modulation of RXR Functions.
Methods Mol Biol. 2019;2019:51-72. doi: 10.1007/978-1-4939-9585-1_4.
7
Retinoid receptors and therapeutic applications of RAR/RXR modulators.
Curr Top Med Chem. 2012;12(6):505-27. doi: 10.2174/156802612799436687.
8
Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor.
Curr Top Med Chem. 2017;17(6):663-675. doi: 10.2174/1568026616666160617092241.
9
Natural and Structure-based RXR Ligand Scaffolds and Their Functions.
Curr Top Med Chem. 2017;17(6):631-662. doi: 10.2174/1568026616666160617072521.
10
Design of selective nuclear receptor modulators: RAR and RXR as a case study.
Nat Rev Drug Discov. 2007 Oct;6(10):811-20. doi: 10.1038/nrd2398.

引用本文的文献

3
A multidisciplinary approach disclosing unexplored Aflatoxin B1 roles in severe impairment of vitamin D mechanisms of action.
Cell Biol Toxicol. 2023 Aug;39(4):1275-1295. doi: 10.1007/s10565-022-09752-y. Epub 2022 Sep 6.
4
Exploring Ligand Binding Domain Dynamics in the NRs Superfamily.
Int J Mol Sci. 2022 Aug 5;23(15):8732. doi: 10.3390/ijms23158732.
6
Retinoid-X receptor agonists increase thyroid hormone competence in lower jaw remodeling of pre-metamorphic Xenopus laevis tadpoles.
PLoS One. 2022 Apr 13;17(4):e0266946. doi: 10.1371/journal.pone.0266946. eCollection 2022.
7
Regulation of Dystroglycan Gene Expression in Early Myoblast Differentiation.
Front Cell Dev Biol. 2022 Mar 7;10:818701. doi: 10.3389/fcell.2022.818701. eCollection 2022.
8
Increased Molecular Flexibility Widens the Gap between and values in Screening for Retinoid X Receptor Modulators.
ACS Med Chem Lett. 2022 Jan 21;13(2):211-217. doi: 10.1021/acsmedchemlett.1c00575. eCollection 2022 Feb 10.
10
DockStream: a docking wrapper to enhance de novo molecular design.
J Cheminform. 2021 Nov 17;13(1):89. doi: 10.1186/s13321-021-00563-7.

本文引用的文献

1
Design of selective nuclear receptor modulators: RAR and RXR as a case study.
Nat Rev Drug Discov. 2007 Oct;6(10):811-20. doi: 10.1038/nrd2398.
2
RAR and RXR modulation in cancer and metabolic disease.
Nat Rev Drug Discov. 2007 Oct;6(10):793-810. doi: 10.1038/nrd2397.
3
Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation.
Cancer Cell. 2007 Jul;12(1):36-51. doi: 10.1016/j.ccr.2007.06.006.
4
RXR is an essential component of the oncogenic PML/RARA complex in vivo.
Cancer Cell. 2007 Jul;12(1):23-35. doi: 10.1016/j.ccr.2007.06.004.
5
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.
Nat Rev Cancer. 2007 May;7(5):357-69. doi: 10.1038/nrc2129. Epub 2007 Apr 19.
6
International Union of Pharmacology. LXIII. Retinoid X receptors.
Pharmacol Rev. 2006 Dec;58(4):760-72. doi: 10.1124/pr.58.4.7.
7
A structure-based approach to retinoid X receptor-alpha inhibition.
J Biol Chem. 2006 Jun 16;281(24):16643-8. doi: 10.1074/jbc.M600318200. Epub 2006 Apr 10.
8
Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM.
Oncogene. 2006 Jun 22;25(26):3735-44. doi: 10.1038/sj.onc.1209410. Epub 2006 Jan 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验